Medical Press Releases

A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth

$SNNC acquires Majority Stake in New Joint Venture With Doc-Rx Opens the Door to Telehealth, U.S.-Made Peptides and an Ambitious Wellness Clinic Expansion Strategy

NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities

October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential

Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline

As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure...

$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company approaches the September 30 expiration of 910,904 publicly traded warrants and continues advancing its AVERSA™ abuse-deterrent...

Today's Proposed Combination Could Significantly Expand CDIX's Healthcare Footprint — While New Equity, Warrants and Exercise Activity Put the Capital Structure Squarely in Focus

With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..

With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts

Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...

NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

Century Fasteners Corp. is pleased to announce the hiring of Michael Maertens, a seasoned financial executive with a proven track record of driving operational excellence and scaling high-growth organizations, as the new Chief Financial Officer.

A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth

$SNNC acquires Majority Stake in New Joint Venture With Doc-Rx Opens the Door to Telehealth, U.S.-Made Peptides and an Ambitious Wellness Clinic Expansion Strategy

NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities

October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential

Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline

As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure...

$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company approaches the September 30 expiration of 910,904 publicly traded warrants and continues advancing its AVERSA™ abuse-deterrent...

Today's Proposed Combination Could Significantly Expand CDIX's Healthcare Footprint — While New Equity, Warrants and Exercise Activity Put the Capital Structure Squarely in Focus

With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..

With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts

Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...

NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...

Neurogut Inc. is proud to announce the granting of US Patent US12575788B2 for its Bioanatoner device, a groundbreaking biofeedback system designed to transform the treatment of anorectal and pelvic floor disorders.

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

Century Fasteners Corp. is pleased to announce the hiring of Michael Maertens, a seasoned financial executive with a proven track record of driving operational excellence and scaling high-growth organizations, as the new Chief Financial Officer.

First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.

At Booth 2J01, imedtac will present four smart healthcare solutions that connect sensing, AI, hospital systems, and clinical workflows to support safer and more efficient care

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

Dr. Harry Mittelman, a Holocaust survivor, U.S. Air Force veteran, medical innovator, educator and longtime Bay Area facial plastic surgeon, has announced his retirement after 52 years of patient care and service to the field of facial plastic and...

Established in 2006, the El Paso location provides a critical nearshoring advantage, enables customers to reduce logistics costs, improve supply chain responsiveness, and helps efficiently manage cross-border production.

Twelve Surgical Centers, Strong Financial Momentum, And A Scalable Growth Strategy Position $CDIX For Its Next Phase Of Expansion

First Commercial Deployment of FDA-Cleared AI-Guided TMS Navigation System, Expanded FDA Pathway for NRX-101, and Growing Commercial Infrastructure Highlight Accelerating Momentum for NRx Pharmaceuticals (N A S D A Q: NRXP)

Strategic Business Transformation, Enterprise Healthcare Expansion, AI-Powered Telehealth Innovation, And Significant Cost Reductions Position $VSEE Health For Potential Multi-Year Growth

Trusted healthcare coordination for advanced treatments and medical travel support.

The NRE Health Institute has announced the launch of the Non-Sexual Nudity Motivations Study (NSNMS), a new international research initiative examining why people support, oppose, follow, consume, discuss, or participate in non-sexual nudity.

Men's Health Network (MHN) today officially kicks off Men's Health Month 2026, celebrating the 31st MHM. 2026 MHM begins with unprecedented momentum.

Expanding HOPE Therapeutics Network Positions NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP for Potential Breakout 2026 Growth

NRx Pharmaceuticals, Inc.Improved Financial Position, Commercial Ketamine Manufacturing, FDA Progress, and Expanding Neuroplastic Therapy Infrastructure Position $NRXP for a Potential Breakout Phase

$CDIX Continues Scaling Its Orthopedic, Spine, and Pain Management Footprint as Revenue Growth, Margin Expansion, and Capital Markets Momentum Accelerate

EyeCool Therapeutics today announced the publication of the first randomized, double‑masked, multicenter clinical trial evaluating its investigational ocular surface cooling device for the treatment of chronic ocular surface pain (COSP) in...

Commercial-Ready Ketamine Production, FDA Alignment, and Expanding AI Neurotherapy Platform Position $NRXP at the Center of a Multi-Billion-Dollar Mental Health Transformation